Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 5/20 | 0.71 |
| ▸ | MEN1 | O00255 | 4/20 | 0.71 |
| ▸ | MAPT | P10636 | 3/20 | 0.71 |
| ▸ | MCOLN3 | Q8TDD5 | 1/20 | 0.71 |
| ▸ | HTT | P42858 | 3/20 | 0.64 |
| ▸ | POLB | P06746 | 2/20 | 0.64 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ATM | Q13315 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 3/20 | 0.42 |
| ▸ | RAB9A | P51151 | 3/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3606448 | 0.84 | ALDH1A1 (0.57) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL1271857 | 0.81 | KMT2A (0.63) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL27787106 | 0.77 | KMT2A (0.51) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL19466440 | 0.75 | MTOR (0.55) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL3600075 | 0.75 | MTOR (0.67) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL629436 | 0.74 | ALDH1A1 (0.44) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL3923572 | 0.72 | POLB (0.46) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL4205443 | 0.72 | POLB (0.46) | KMT2AMEN1MAPTMCOLN3HTT | |
| SCHEMBL3404366 | 0.72 | ALDH1A1 (0.53) | KMT2AMEN1POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL24287407 | 0.71 | GAA (0.58) | KMT2AMEN1MAPTPOLBALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2057140-B1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2012-08-08 | — | — | EP | disclosed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2010-09-09 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| US-7750003-B2 | Compounds-943 | ASTRAZENECA AB (SE) | 2010-07-06 | — | — | US | disclosed |
| EP-2176256-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | AstraZeneca AB (SE) | 2010-04-21 | — | — | EP | disclosed |
| EP-2057140-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | AstraZeneca AB (SE) | 2009-05-13 | — | — | EP | disclosed |
| WO-2009007751-A2 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | ASTRAZENECA AB (SE) | 2009-01-15 | — | — | WO | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| US-20080171743-A1 | Transcutaneous immunostimulation | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | US | disclosed |
| WO-2008023159-A1 | MORPHOLINO PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF PROLIFERATIVE DISORDERS | ASTRAZENECA AB (SE) | 2008-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080171743-A1 | Transcutaneous immunostimulation | NFATC1, TLR9, MTOR | KMT2A 2735/4885MEN1 2336/4885MAPT 2339/4885 |
| US-20100227858-A1 | TRISUBSTITUTED PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PROLIFERATIVE DISEASES | MTOR, PIK3CA, PIK3CD | KMT2A 2839/4885MEN1 3142/4885MAPT 1480/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.